Earnings Summary

Regeneron Pharmaceuticals, Inc.’s revenue jumped 10.53% since last year same period to $3158.1Mn in the Q2 2023. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated -0.13% fall in its revenue since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit jumped 13.65% since last year same period to $968.4Mn in the Q2 2023. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated 18.42% jump in its net profits since last 3-months.

Regeneron Pharmaceuticals, Inc.’s net profit margin jumped 2.82% since last year same period to 30.66% in the Q2 2023. On a quarterly growth basis, Regeneron Pharmaceuticals, Inc. has generated 18.57% jump in its net profit margins since last 3-months.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 10.61 - a 11.92% jump from last quarter’s estimates.

Regeneron Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 10.61.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Regeneron Pharmaceuticals, Inc.’s return on assets (ROA) stands at 0.1.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Regeneron Pharmaceuticals, Inc.’s return on equity (ROE) stands at 0.19.